Transdermally administered tolterodine as anti-muscarinic agent for the treatment of overactive bladder
AssigneePfizer Health AB
InventorsLene Orup Jacobsen, Bo Kreilgard, Ulla Hoeck, Helle Kristensen
Life of this patent
Estimating the term…
Abstract
The present invention is drawn to set of formulations of at least one compound selected from tolterodine, salts thereof, prodrugs thereof and/or metabolites thereof, wherein in the set of formulations contains at least one device for transdermal administration and at least one formulation for oral, sublingual, buccal, nasal, pulmonary, rectal and/or other transmucosal administration, in order to achieve an effect against overactive bladder and/or symptoms associated with this condition. The present invention is further drawn to methods of treating an overactive bladder with the formulations.
Claims25
A delivery system comprising:
- at least one compound selected from the group consisting of R-tolterodine, salts thereof, prodrugs thereof and metabolites thereof;
- and
- at least one device for transdermal administration of said at least one compound, said device selected from the group consisting of a reservoir, a matrix, a drug-in-adhesive, a multi-laminate, a polymer-system with no foils, an iontophoretic and combinations thereof, an electroporation, an electroosmosis, an electroincorporation a jet injection device, said device containing said at least one compound, and said device having an hourly flux rate of tolterodine of about 0.1 μg/h/cm2 to about 100 μg/h/cm2;
- and
- at least one formulation for oral, sublingual, buccal, nasal, pulmonary, rectal and/or other transmucosal administration of said at least one compound, to a human being or an animal in order to achieve an effect against overactive bladder and/or symptoms associated with this condition.
A delivery system comprising:
- at least one compound having a therapeutic effect against an overactive bladder in a living body which is selected from the group consisting of (R)-tolterodine or the racemate thereof, salts thereof, prodrugs thereof, and metabolites thereof;
- a transdermal administration device selected from the group consisting of a reservoir, a matrix, a drug-in-adhesive, a multi-laminate, a polymer-system with no foils, a iontophoretic device, and combinations thereof, an electroporation, an electroosmosis, an electroincorporation and a jet injection device which contains said compound and which has an hourly flux rate of said at least one compound from about 0.1 μg/h/cm2 to about 100 μg/h/cm2;
- and at least one formulation for oral, sublingual, buccal, nasal, pulmonary, rectal and/or other transmucosal administration.
Dependencies are inferred from the claim text.